0001193125-21-317734.txt : 20211103 0001193125-21-317734.hdr.sgml : 20211103 20211103080059 ACCESSION NUMBER: 0001193125-21-317734 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20211102 ITEM INFORMATION: Regulation FD Disclosure ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20211103 DATE AS OF CHANGE: 20211103 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Landos Biopharma, Inc. CENTRAL INDEX KEY: 0001785345 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 815085535 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-39971 FILM NUMBER: 211373769 BUSINESS ADDRESS: STREET 1: 1800 KRAFT DRIVE, SUITE 216 CITY: BLACKSBURG STATE: VA ZIP: 24060 BUSINESS PHONE: 540-818-2844 MAIL ADDRESS: STREET 1: 1800 KRAFT DRIVE, SUITE 216 CITY: BLACKSBURG STATE: VA ZIP: 24060 8-K 1 d240596d8k.htm 8-K 8-K
false 0001785345 0001785345 2021-11-02 2021-11-02

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d)

OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) November 2, 2021

 

 

Landos Biopharma, Inc.

(Exact name of Registrant as Specified in its Charter)

 

 

 

Delaware   001-39971   81-5085535

(State or Other Jurisdiction

of Incorporation)

 

(Commission

file Number)

 

(IRS Employer

Identification No.)

 

1800 Kraft Drive, Suite 216, Blacksburg, Virginia   24060
(Address of Principal Executive Offices)   (Zip Code)

Registrant’s telephone number, including area code (540) 218-2232

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-2 under the Exchange Act (17 CFR 240.14a-2)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

 

Trading

Symbol(s)

 

Name of each exchange

on which registered

Common Stock, par value $0.01 per share   LABP   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company  

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  

 

 

 


Item 7.01

Regulation FD Disclosure.

On November 2, 2021, Landos Biopharma, Inc. issued the press release furnished herewith as Exhibit 99.1 to announce that the U.S. Food and Drug Administration has cleared Landos’ Investigational New Drug application for LABP-104, a novel, oral, systemically delivered LANCL2 agonist, for the treatment of rheumatoid arthritis.

The information in this Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

 

Item 9.01

Financial Statements and Exhibits.

(d) Exhibits

 

99.1    Press Release of Landos Biopharma, Inc., dated November 2, 2021
104    The cover page from Landos Biopharma, Inc.’s Form 8-K filed on November 3, 2021, formatted in Inline XBRL.


SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized on this 3rd day of November, 2021.

 

LANDOS BIOPHARMA, INC.
By:  

/s/ Josep Bassaganya-Riera

Name:   Josep Bassaganya-Riera
Title:   Chairman, President and Chief Executive Officer
EX-99.1 2 d240596dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

Landos Biopharma Announces FDA Clearance of its IND for LABP-104 for the Treatment of Rheumatoid Arthritis

Phase 1 trial is underway with topline results expected in the first half of 2022

Represents Landos’ seventh IND cleared overall and the second IND cleared for LABP-104, a potentially first-in-class therapeutic candidate for systemic lupus erythematosus and rheumatoid arthritis

BLACKSBURG, Va., Nov. 02, 2021 (GLOBE NEWSWIRE) — Landos Biopharma, Inc. (NASDAQ: LABP), a late clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has cleared the Company’s Investigational New Drug (IND) application for LABP-104, a novel, oral, systemically delivered LANCL2 agonist, for the treatment of rheumatoid arthritis (RA). The FDA has recently cleared an IND application for LABP-104 for the treatment of systemic lupus erythematosus (SLE). Landos has initiated a Phase 1 trial of LABP-104 for the treatment of RA and SLE in healthy volunteers and expects to report topline results in the first half of 2022.

“Our team continues to successfully and timely deliver on the goals we set out at the beginning of the year, notably to clear three INDs in 2021. The FDA clearance of the LABP-104 IND application in RA is Landos’ seventh successful IND approval derived from our LANCE A.I. platform in less than four years,” commented Josep Bassaganya-Riera, Chairman, President and Chief Executive Officer of Landos. “LABP-104 has reduced inflammatory cell infiltration and its LANCL2 mechanism showed significantly less risk for toxicities than biologic and JAK inhibitor treatments currently available. As RA patients are prone to relapse, we are inspired by the opportunity to develop a candidate that could potentially redefine the treatment paradigm as a therapy that helps maintain clinical remission and overall survival for these patients, while improving their quality of life.”

Like omilancor, Landos’s Phase 3-ready therapeutic candidate for UC, LABP-104 targets the anti-inflammatory receptor LANCL2, a novel mechanism for enhancing Treg function and decreasing TNF production. In a collagen-induced mouse model of arthritis, oral treatment with LABP-104 provided protection from severity of disease, including a significant reduction of redness and swelling in addition to overall paw size. Consistent with the validated actions of the LANCL2 pathway in other indications, with once-daily oral dosing, LABP-104 significantly reduced the numbers of Th17 and T follicular helper cells in the spleen while increasing the number of CD25high FOXP3+ Tregs.

The Phase 1 trial is a randomized, placebo-controlled, double-blind, ascending dose, multi-cohort study designed to evaluate the safety, tolerability and pharmacokinetics of LABP-104 in healthy volunteers. A total of 56 healthy volunteers will be enrolled in two parts – a single ascending dose study (SAD) and then a multiple ascending dose study (MAD), during which the participants will be randomized to five cohorts receiving single oral doses of LABP-104 or placebo in the SAD and to three cohorts receiving three oral doses of LABP-104 or placebo once daily for seven days in the MAD. The primary endpoint will measure the safety and tolerability of LABP-104. Secondary endpoint will measure the pharmacokinetics of LABP-104. We expect to report topline results of the Phase 1 trial in the first half of 2022. Additional information about the Phase 1 LABP-104 trial for SLE and RA is available at clinicaltrials.gov (NCT05019950).


About Rheumatoid Arthritis (RA)

Rheumatoid arthritis (RA) is an autoimmune disease characterized by over-activation of the immune system and increased immune cell infiltration that results in chronic pain and loss of mobility due to excessive inflammation that swell joints and erode bone and cartilage. Current therapies in RA have limitations tied to safety and efficacy and are often accompanied by a high risk of severe side effects and co-morbidities. Furthermore, RA requires chronic treatment to maintain clinical remission. RA affects 1.3 million patients in the United States, with the number of new cases expected to increase as the elderly population grows. According to Global Data, in 2021, sales of prescription drugs to treat RA are estimated to total $20.9 billion. The US currently comprises approximately 74% of the total global prescription sales.

About LABP-104

LABP-104 is an oral, systemically distributed, small-molecule therapeutic candidate which activates LANCL2, a surface membrane-associated receptor that is responsible for modulating key cellular and molecular changes tied to autoimmune diseases. LABP-104 is currently in clinical development for systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). To date, treatment with LABP-104 has reduced the production of interferon alpha in human PBMCs from SLE patients and provided protection from clinical disease and tissue pathology in mouse models of lupus. Landos has initiated a Phase 1 trial of LABP-104 in healthy volunteers for the treatment of SLE and RA, with topline results expected the first half of 2022. In preclinical models of RA, LABP-104 has resulted in decreased tissue-damaging Th17 and Tfh cells with increased protective Tregs for RA. Landos owns an issued patent on LABP-104 in the U.S., a number of foreign patent applications, and an international patent application available for filing in additional foreign countries and regions through the Patent Cooperation Treaty.

About Landos Biopharma

Landos Biopharma is a late-clinical-stage biopharmaceutical company utilizing its LANCE® Advanced A.I. platform to discover and develop novel therapeutics for patients with autoimmune diseases. Using the LANCE® platform, the Company has discovered new mechanisms of action, including the LANCL2, NLRX1 and PLXDC2 immunometabolic pathways. Landos Biopharma has 17 active development programs targeting these novel pathways at the interface of immunity and metabolism. Its lead product candidate, omilancor targets the LANCL2 pathway and is a novel oral, gut-restricted, small-molecule potentially first-in-class therapeutic currently being prepared for global pivotal Phase 3 trials for the treatment of ulcerative colitis, in two active Phase 2 trials in Crohn’s disease, and is anticipated to initiate Phase 1 studies in eosinophilic esophagitis in 2022. Omilancor is also being studied in a topical formulation for psoriasis and atopic dermatitis. NX-13 is a novel, oral, gut-restricted small-molecule drug candidate that targets the NLRX1 pathway and is currently in an active Phase 1b trial in ulcerative colitis. NX-13 targets the NLRX1 pathway. Landos’ seventh new clinical product candidate, LABP-104, is in an active Phase 1 trial for systemic lupus erythematosus and rheumatoid arthritis, guided by a proprietary 15-gene precision medicine companion diagnostic developed by its LANCE® advanced A.I. platform. Additional product candidates in Landos’ expansible inflammation and immunology pipeline are in preclinical and IND-enabling stages of development. For more information, please visit www.landosbiopharma.com.


Cautionary Note on Forward-Looking Statements Statements in this press release about future expectations, plans and prospects for Landos Biopharma, Inc. (the “Company”), including statements about the Company’s strategy, clinical development and regulatory plans for its product candidates, the Company’s anticipated milestones and future expectations and plans and prospects for the Company and other statements containing the words “anticipate”, “plan”, “expect”, “may”, “will”, “could”, the negatives thereof, variations thereon and similar expressions, or any discussions of strategy constitute forward-looking statements. Actual results may differ materially from those indicated by such forward-looking statements as a result of various important factors, including: the uncertainties inherent in the initiation and enrollment of future clinical trials, expectations of expanding ongoing clinical trials, availability and timing of data from ongoing clinical trials, expectations for regulatory approvals, other matters that could affect the availability or commercial potential of the Company’s product candidates and other similar risks. Risks regarding the Company’s business are described in detail in its Securities and Exchange Commission (“SEC”) filings, including in its Annual Reports on Form 10-K and Quarterly Reports on Form 10-Q, which are available on the SEC’s website at www.sec.gov. Additional information will be made available in other filings that the Company makes from time to time with the SEC. Such risks may be amplified by the impacts of the COVID-19 pandemic. In addition, the forward-looking statements included in this press release represent the Company’s views only as of the date hereof. The Company anticipates that subsequent events and developments will cause the Company’s views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, the Company specifically disclaims any obligation to do so, except as may be required by law. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date hereof.

Contacts:

Marek Ciszewski, J.D.

Landos Biopharma

562-373-5787

IR@LandosBiopharma.com

Michael K. Levitan (investors)

Solebury Trout

646-378-2920

mlevitan@soleburytrout.com

Hannah Gendel (media)

Solebury Trout

646-378-2943

hgendel@soleburytrout.com

EX-101.SCH 3 labp-20211102.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 labp-20211102_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Two Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period EX-101.PRE 5 labp-20211102_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 6 d240596d8k_htm.xml IDEA: XBRL DOCUMENT 0001785345 2021-11-02 2021-11-02 false 0001785345 8-K 2021-11-02 Landos Biopharma, Inc. DE 001-39971 81-5085535 1800 Kraft Drive Suite 216 Blacksburg VA 24060 (540) 218-2232 false false false false Common Stock, par value $0.01 per share LABP NASDAQ true true XML 7 R1.htm IDEA: XBRL DOCUMENT v3.21.2
Document and Entity Information
Nov. 02, 2021
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001785345
Document Type 8-K
Document Period End Date Nov. 02, 2021
Entity Registrant Name Landos Biopharma, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-39971
Entity Tax Identification Number 81-5085535
Entity Address, Address Line One 1800 Kraft Drive
Entity Address, Address Line Two Suite 216
Entity Address, City or Town Blacksburg
Entity Address, State or Province VA
Entity Address, Postal Zip Code 24060
City Area Code (540)
Local Phone Number 218-2232
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.01 per share
Trading Symbol LABP
Security Exchange Name NASDAQ
Entity Emerging Growth Company true
Entity Ex Transition Period true
EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx M4$L#!!0 ( !Q 8U,'04UB@0 +$ 0 9&]C4')O<',O87!P+GAM M;$V./0L",1!$_\IQO;=!P4)B0-!2L+(/>QLOD&1#LD)^OCG!CVX>;QA&WPIG M*N*I#BV&5(_C(I(/ !47BK9.7:=N')=HI6-Y #OGDK7A.YNJQ<&4GPZ4A!0W_J=0U[R;UEA_6\#MI7E!+ P04 M " <0&-3M_#A-.X K @ $0 &1O8U!R;W!S+V-O&ULS9+/ M2L0P$(=?17)O)VEQ#Z';B^))07!!\1:2V=U@\X=DI-VW-ZV[740?P&-F?OGF M&YA.1ZE#PN<4(B:RF&\F-_@L==RR(U&4 %D?T:EG;-?4.([UV"ZYLH. MZ?'EV7=ROI, MRFLLO[*5=(JX99?)K^W=_>Z!]0UO1"5$Q=N=:"3G\G;S/KO^\+L*NV#LWOYC MXXM@W\&ON^B_ %!+ P04 " <0&-3F5R<(Q & "<)P $P 'AL+W1H M96UE+W1H96UE,2YX;6SM6EMSVC@4?N^OT'AG]FT+QC:!MK03621A'^_1S80RY8-[9)-NIL\!"SI^\Y%1^?H.'GS[BYBZ(:(E/)X M8-DOV]:[MR_>X%#BVR]*+ M41B1%G\@M MNN01.+5)#3(3/PB=AIAJ4!P"I DQEJ&&^+3&K!'@$WVWO@C(WXV(]ZMOFCU7 MH5A)VH3X$$8:XIQSYG/1;/L'I4;1]E6\W*.76!4!EQC?-*HU+,76>)7 \:V< M/!T3$LV4"P9!AI@S M&L%&KQMUAVC2/'K^!?F<-0HACA*FNVB<5@$_9Y>PTG!Z(++9OVX?H;5,VPLCO='U!=*Y \FIS_I,C0' MHYI9";V$5FJ?JH,@H%\;D>/N5Z> HWEL:\4*Z">P'_T=HWPJOX@L Y M?RY]SZ7ON?0]H=*W-R-]9\'3BUO>1FY;Q/NN,=K7-"XH8U=RSTS0LS0[=R2^JVE+ZU)CA* M]+',<$X>RPP[9SR2';9WH!TU^_9==N0CI3!3ET.X&D*^ VVZG=PZ.)Z8D;D* MTU*0;\/YZ<5X&N(YV02Y?9A7;>?8T='[Y\%1L*/O/)8=QXCRHB'NH8:8S\-# MAWE[7YAGE<90-!1M;*PD+$:W8+C7\2P4X&1@+: '@Z]1 O)256 Q6\8#*Y"B M?$R,1>APYY=<7^/1DN/;IF6U;J\I=QEM(E(YPFF8$V>KRMYEL<%5'<]56_*P MOFH]M!5.S_Y9KF4Q9Z;RWRT,"2Q;B%D2XDU=[=7GFYRN>B)V^I=W MP6#R_7#)1P_E.^=?]%U#KG[VW>/Z;I,[2$R<><41 71% B.5' 86%S+D4.Z2 MD 83 >LX=SFWJXPD6L_UC6'ODRWSEPVSK> U[F M$RQ#I'[!?8J*@!&K8KZZKT_Y)9P[M'OQ@2";_-;;I/;=X Q\U*M:I60K$3]+ M!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F 6/,,H68XWX=%FAHSU8NL.8T*;T'5 M0.4_V]0-:/8--!R1!5XQF;8VH^1."CS<_N\-L,+$CN'MB[\!4$L#!!0 ( M !Q 8U-:42_ 9@0 'D1 8 >&PO=V]R:W-H965T&UL MG9A=<^(V%(:OM[]"P_2BG2&Q)3ZS0Y@!DK299+-LH+LS[?1"V (TL2U7D@/Y M]SVRP98"MB;BY5 M*A)XLE8ZYA:*>N.95 L>YHWBR&.^W_=B+I/6>)3?F^OQ2&4VDHF8:V*R..;Z M;2HBM;MNT=;QQK/<;*V[X8U'*=^(A;!_I',-):]4"64L$B-50K187[(*]^%URW=$(A*!=1(<_E[%3$214P*.?PZBK?*= MKN'[ZZ/Z7=YYZ,R*&S%3T3<9VNUU:]@BH5CS+++/:O>[.'2HY_0"%9G\E^R* MNEV_18+,6!4?&@-!+)/BG^\/@3BG 3LT8#EW\:*<\H9;/AYIM2/:U08U=Y%W M-6\-<#)QH[*P&IY*:&?'-RK((,B6\"0DMXF5]HW<)\5H0]1&GH67N*I>KTD/FL3YC/Z?7,/V$I 5@*R7*]S0F^F7H4F?TU6QFH8PK\1R4XI MVQ%L= M$:[D^SX=#'N=;@_!ZI58/52L3(GE6RKJ6/#FPXL'!*)?0O3/@Y@++95+S9! M@M?RX$IY0K+V3Q\^-&3DH$0;G#-LSV(C74X"XQ./:\%PG4>8CYPUZO@TU(^LZDZ3F$DS#4PICV\8(\0CWR.:D=R@9).O1]\J#YVI(;#0LC MQEEY-67_GW.Y4[6,-9A&%&U%E#JY%'AX!,ZS8^,#^$#:=G]?K^O%KT&LD MJWR?X2;]'[)[8S(@:P3$91L!WVW.&]Q9!)EVTX^R%5E*&]5.OP81U\-\AZ*" MES9)N2:O/,H$^=F_]"E)H:,&-D@H<+4 ,-RQEYJ'+O$6;_%*U:9=@\#C9#K' M2"JS9[@QEZ&[W0=;GFS$R6UD@]#39'$S^8(Q52[/SG+YVUCHC8O2;Z!@MRX% M4Y[4GDL:!*W.T'&K/)[A%GTDVQ,8P<3(?'M6G UJL7"U4UC>NX.T^RCQB;LX M&!*)->CXEP/HK2[.^47!JC0_6Z^4A9-Z?KD5'.:FJP#/UTK98\$=U\NO+>-_ M 5!+ P04 " <0&-3GZ ;\+$" #B# #0 'AL+W-T>6QEO%DN7/ZZZ>S;"=I=67= MA['-HN6/O.-%Q[I#)6 M,>=56R=M8SDK6W!2,EG>W&2)8D+38JT[=:=<2PZFTVY#;VA2K"NCSY:4!H-? MRA0GCTQNZ)9)L;=B6,N4D*=@7H+A8*2QQ'DJ?$,78&F? KP(&K XU7=>&18/QA<0&>7=J?$,:\M.B^4M M/3L,/S[)WMB2VSG-@DZF8BUY!72LJ(_PZTR3 .B<45XH!:N-9@.'R6,4?-@# ME_(!6OBMNHK=5R3TXE,);2"PU4GTA$8QA D*Q+^,%F)?A+W]K;"D$8_&?>S\ M;O2@?^^,X_>65Z(?]+Z:\V/1%WATUC3R]$&*6BL>]O[+"8LUF_S(T5CQY+/! MI!R\@5M*'KEUXG!I^6%9L^.]FZ:IKW#.RW^0\Y^M<\TUMTQ>DO:C_S=7^2V, MD_'T7!S1JP,Z6PEY7>>9 ]IV03NA1.XJRY/K%.?7A'=O["_PJOE]? M\HIUTNUF<$//\A=>BD[E\ZI[J,NXZBQ_AOMHD M\%G'!QR>(W?#$T%^@2O M&+(=/EB>N$_NG_A.\SQ-LPRKZ'8;9;#%ZI9E\!>/AG$##RP/9'I;K?%NXQ/R M^AQ@/7UM0K"=XI.([12O-2#QNH%'GL>[C>4!#ZP+V.Q _G@>F*FX3YI"5S%N MV G&D3S'$)C%^(QF&5*=##[Q_F"G)$WS/(X %F>0IA@"IQ%', ; 4/2='@/ M/GL?)=-[*CG_5U/\!%!+ P04 " <0&-3EXJ[', 3 @ "P %]R M96QS+RYR96QSG9*Y;L,P#$!_Q=">, ?0(8@S9?$6!/D!5J(/V!(%BD6=OZ_: MI7&0"QEY/3P2W!YI0.TXI+:+J1C]$%)I6M6X 4BV)8]ISI%"KM0L'C6'TD!$ MVV-#L%HL/D N&6:WO606IW.D5XA-/E_G;@2=&A(E@6FD7)TZ(=I7\=Q_:0T^FO8R*T>EOH M^7%H5 J.W&,EC'%BM/XU@LD/['X 4$L#!!0 ( !Q 8U,<.&7J/P$ #P" M / >&PO=V]R:V)O;VLN>&ULC5'+;L) #/R5U7Y $U"+5$2XE#Z0JA:5 MBON2=8C%/B*O RU?7R=15*1>>O)Z;(UG9A?G2,=]C$?UY5U(A:Z9FWF6I;(& M;])-;"#(I(KD#4M+ARPU!,:F&H"]RZ9Y/LN\P:"7BY%K0]EU$QE*QA@$[( = MPCG]SKM6G3#A'AWR=Z'[MP.M/ ;T> %;Z%RK5,?S2R2\Q,#&;4N*SA5Z,@QV M0(SE'WC;B?PT^]0C;/8?1H04>I8+8864N-_H^8UH/($L#UW+\0D= ZT,PS/% MML%PZ&C$179EH\]AK$.(<_I/C+&JL(15+%L/@8<<"5PG,*0:FZ15,!X*/:XH M$ZQZ#"PAJ748J&2WEYIK=WDWM)J'7N0;#W\!J-'[IFBG#S^ M0W1UW6E\./VR./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@ MXLD@;6E6?;!/3K3G>1,)KM\,<'AT_@%02P,$% @ '$!C4V60 M>9(9 0 SP, !, !;0V]N=&5N=%]4>7!E&ULK9--3L,P$(6O$F5; M)2XL6*"F&V +77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B= M]=B4'5%\% )5!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T M.EY&TWP39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JK MA%SY'7#J>SM 2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$# M(&?KT70Q32:>,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[ M04Y;@[Z1S>/]#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%0 M2P$"% ,4 " <0&-3!T%-8H$ "Q $ @ $ M9&]C4')O<',O87!P+GAM;%!+ 0(4 Q0 ( !Q 8U.W\.$T[@ "L" 1 M " :\ !D;V-0&UL4$L! A0#% @ '$!C4UI1+\!F! >1$ !@ M ("!#0@ 'AL+W=O*NQS $P( L ( ! MA0\ %]R96QS+RYR96QS4$L! A0#% @ '$!C4QPX9>H_ 0 / ( \ M ( !;A 'AL+W=O7!E&UL4$L%!@ ) D */@( D4 $! end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.21.2 html 1 96 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d240596d8k.htm d240596dex991.htm labp-20211102.xsd labp-20211102_lab.xml labp-20211102_pre.xml http://xbrl.sec.gov/dei/2020-01-31 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d240596d8k.htm": { "axisCustom": 0, "axisStandard": 0, "contextCount": 1, "dts": { "inline": { "local": [ "d240596d8k.htm" ] }, "labelLink": { "local": [ "labp-20211102_lab.xml" ] }, "presentationLink": { "local": [ "labp-20211102_pre.xml" ] }, "schema": { "local": [ "labp-20211102.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "https://xbrl.sec.gov/dei/2020/dei-2020-01-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://xbrl.sec.gov/naics/2017/naics-2017-01-31.xsd", "http://www.xbrl.org/lrr/role/deprecated-2009-12-16.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2020-01-31": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 96, "memberCustom": 0, "memberStandard": 0, "nsprefix": "labp", "nsuri": "http://imetrix.edgar-online.com/20211102", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d240596d8k.htm", "contextRef": "duration_2021-11-02_to_2021-11-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "role": "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "p", "div", "div", "body", "html" ], "baseRef": "d240596d8k.htm", "contextRef": "duration_2021-11-02_to_2021-11-02", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressAddressLine2": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 2 such as Street or Suite number", "label": "Entity Address, Address Line Two", "terseLabel": "Entity Address, Address Line Two" } } }, "localname": "EntityAddressAddressLine2", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityExTransitionPeriod": { "auth_ref": [ "r7" ], "lang": { "en-us": { "role": { "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.", "label": "Entity Ex Transition Period", "terseLabel": "Entity Ex Transition Period" } } }, "localname": "EntityExTransitionPeriod", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2020-01-31", "presentation": [ "http://imetrix.edgar-online.com//20211102/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12" }, "r5": { "Name": "Regulation 12B", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425" }, "r7": { "Name": "Securities Act", "Number": "7A", "Publisher": "SEC", "Section": "B", "Subsection": "2" } }, "version": "2.1" } ZIP 14 0001193125-21-317734-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-21-317734-xbrl.zip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end